HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.2
  1. Home
  2. /Compound

Dordaviprone

HCID 73777259
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
1616632-77-9
Standard SMILES
Cc1ccccc1CN1C(=O)C2=C(CCN(Cc3ccccc3)C2)N2CCN=C12
InChIKey
VLULRUCCHYVXOH-UHFFFAOYSA-N
Molecular formula
C24H26N4O
Average molar mass
386.5 g/mol
Monoisotopic mass
386.21066147

Overview

Dordaviprone is an organic heterotricyclic compound that is 2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one substituted by 2-methylbenzyl and benzyl groups at positions 4 and 7, respectively. It is a selective antagonist of the dopamine receptor D2 and an allosteric agonist of mitochondrial protease caseinolytic protease P. It has a role as a dopamine receptor D2 antagonist, an antineoplastic agent and an apoptosis inducer. It is a member of benzenes, an organic heterotricyclic compound and a member of toluenes.

Names & identifiers

Preferred name
Dordaviprone
IUPAC
11-benzyl-7-[(2-methylphenyl)methyl]-2,5,7,11-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5-dien-8-one
English name
TIC10
Molecular formula
C24H26N4O
Molecular weight
386.49

Names & synonyms

1616632-77-9DordaviproneONC201ONC 201ONC-2019U35A31JAINSC-3506252,4,6,7,8,9-Hexahydro-4-((2-methylphenyl)methyl)-7-phenylmethyl)imidazo)(1,2-a)pyrido(3,4-e)pyrimidin-5(1H)-oneRefChem:920624Akt/ERK Inhibitor ONC2017-Benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5(4H)-onedordaviprona
Show more names
imipridoneDordaviprone hydrochloride7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-oneTIC10CS-2579ONC201,TIC10TIC-10 (ON201)TIC10(ONC-201)
TIC10 compoundMFCD28118993UNII-9U35A31JAI11-benzyl-7-[(2-methylphenyl)methyl]-2,5,7,11-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5-dien-8-oneTIC10 (ONC201)ModeysoNSC 350625Imidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, 2,4,6,7,8,9-hexahydro-4-[(2-methylphenyl)methyl]-7-(phenylmethyl)-

Properties

Computed structural properties

XLogP
2.3
Topological polar surface area
39.2 Ų
Hydrogen bond donors
0
Hydrogen bond acceptors
3
Rotatable bonds
4
Heavy atoms
29
Formal charge
0
Complexity
693

Physicochemical properties

Boiling point
559.7 · 559.7±60.0 °C(Predicted)
Density
1.24 · 1.24±0.1 g/cm3(Predicted)
storage temp.
-20 °C · Sealed in dry,Store in freezer, under -20°C
solubility
Soluble in DMSO (up to 25 mg/ml with warming).
pka
6.38 · 6.38±0.20(Predicted)
form
solid
color
Pale yellow
Stability
1 year · Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 2 months.
InChI
InChI=1S/C24H26N4O/c1-18-7-5-6-10-20(18)16-28-23(29)21-17-26(15-19-8-3-2-4-9-19)13-11-22(21)27-14-12-25-24(27)28/h2-10H,11-17H2,1H3
InChIKey
VLULRUCCHYVXOH-UHFFFAOYSA-N
SMILES
C12=NCCN1C1CCN(CC3=CC=CC=C3)CC=1C(=O)N2CC1=CC=CC=C1C
FDA UNII
9 U35A31JAI · 9U35A31JAI
Symbol(GHS)
7 · GHS07
Signal word
Warning

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Safety data

Signal word
Warning
Symbol(GHS)
GHS07
Hazard statements
H315-H319-H335
Precautionary statements
P264-P280-P302+P352-P321-P332+P313-P362-P305+P351+P338-P337+P313-P261-P271-P304+P340-P312-P403+P233-P405-P501

Chemistry & industry

Pharmacology

Protein BindingDordaviprone plasma protein binding is 95% to 97% and independent of concentrations in vitro.
Pharmacodynamics · 1 item

Dordaviprone is a drug with anti-tumour activity: It exhibited anti-tumour activity in cell-based assays and in vivo models of H3 K27M-mutant diffuse glioma. Dordaviprone causes a concentration-dependent QTc interval prolongation. At 1.2 times the maximum recommended dose, the estimated mean QTcF change was 11.8 msec (90% CI: 9.8, 13.7). The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of dordaviprone have not been fully characterized.

Mechanism of Action · 1 item

Dordaviprone is a protease activator of the mitochondrial caseinolytic protease P (ClpP), a mitochondrial serine protease. Diffuse midline gliomas harboring an H3 K27M mutation are associated with the loss of H3 K27 trimethylation. In vitro, dordaviprone induced apoptosis and altered mitochondrial metabolism leading to restored histone H3 K27 trimethylation in H3 K27M-mutant diffuse glioma models. Dordaviprone activates ATF4 and induces endoplasmic reticulum (ER) stress response or integrated stress response (ISR). Dordaviprone also inhibits the dopamine D2 receptor, which are often overexpressed in multiple cancers, including glioblastoma.

Biological Half-LifeDordaviprone mean terminal half-life is 11 hours (30%).
Metabolism/MetabolitesDordaviprone is primarily metabolized by CYP3A4 with minor contribution from CYP2B6, CYP2C8, CYP2C9, CYP2D6, and CYP3A5. The metabolic pathways and the metabolites have not been fully characterized.
FDA Pharmacological Classification · 5 items

9U35A31JAI

DORDAVIPRONE

Established Pharmacologic Class [EPC] - Protease Activator

Mechanisms of Action [MoA] - Protease Activators

Dordaviprone is a Protease Activator. The mechanism of action of dordaviprone is as a Protease Activator.

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

Database identifiers

CAS
1616632-77-9
PubChem CID
73777259
DTXSID
DTXSID701356572
ChEMBL
CHEMBL4297310
ChEBI
CHEBI:232328
UNII
9U35A31JAI
Hazard statements
315 · H315-H319-H335
Precautionary statements
264 · P264-P280-P302+P352-P321-P332+P313-P362-P305+P351+P338-P337+P313-P261-P271-P304+P340-P312-P403+P233-P405-P501
MeSH Pharmacological Classification
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Absorption, Distribution and Excretion · 4 items

Dordaviprone maximum concentration (Cmax) is 2.8 mcg/mL (42%), and total systemic exposure (AUC) is 23 hr x mcg/mL (48%). Dordaviprone Cmax and AUC increased in a dose proportional manner over the dose range of 125 to 625 mg. Dordaviprone median (min, max) time to maximum plasma concentration (Tmax) is 1.4 hours (0.5, 5.6 hours). Dordaviprone Cmax decreased by 40% with no change on AUC following administration with a high-fat meal (800 to 1,000 calories, 50% fat).

Following a single dose of radiolabeled dordaviprone, about 70% of the dose was recovered in urine and 20% in feces with no notable unchanged dordaviprone in urine or feces.

Dordaviprone apparent (oral) volume of distribution is 450 L (40%). The median blood-to-plasma ratio is 0.67 in vitro. Dordaviprone crosses the blood-brain barrier.

The apparent clearance is approximately 27 L/hr (48%).

Applications · 2 items

DescriptionTIC10 induces the expression of TNF-related apoptosis-inducing ligand (TRAIL) at 1-5 μM in a p53-independent manner. It is orally active, stable, and crosses the blood-brain barrier. The induction of TRAIL results from dual inhibition of Akt and ERK1/2 combined with nuclear translocation of the transcription factor FOXO3a. TIC10 suppresses the growth of orthotopic human glioblastoma multiforme tumors in mice.

Uses7-Benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one is used in biological studies for structure confirmation and pharmacophore reassignment for induction of immunosurveillance cytokine TRAIL in macrophages. The structure of this compound was misassigned for many years as H291055. The resolution of this issue was recently highlighted in Chemical and Engeneering News 92(23) 32 (2014).

Upstream & downstream products

Upstream raw materials

4,5-dihydro-N-[(2-methylphenyl)methyl]-1H-Imidazol-2-amineMethyl 1-benzyl-4-oxo-3-piperidine-carboxylate hydrochlorideSodium MethoxideMethanol